BioDelivery Sciences International is shutting down its New Jersey laboratory and consolidating its operations in Raleigh, a move that will save the company nearly $1 million in annual costs.
The company announced today that it decided it no longer needs its Newark facility, which employs four workers, now that the experimental drug Bioral Amphotericin B, an anti-fungal treatment, is in clinical trials. Bioral Amphotericin is an oral version of Amphotericin, a drug
that is only available intravenously.
In July BioDelivery won federal regulatory approval for its first product, an oral pain patch for cancer patients called Onsolis.